Other News

LIVEMETRIC RECEIVES FDA CLEARANCE FOR ITS WATCH-LIKE WEARABLE BLOOD PRESSURE MONITORING TECHNOLOGY, A LONG-AWAITED REVOLUTION IN CUFF-FREE HYPERTENSION MONITORING

LiveMetric is launching LiveOne, an FDA-cleared wearable technology for health systems, health insurers, and self-insured employers to improve the care and treatment of people with hypertension and cardiovascular disease.  DENVER and LUXEMBOURG, June 30, 2022 /PRNewswire/ — LiveMetric, a leader in medical wearable technology, today announced the launch of LiveOne, the world’s first 510(k) U.S. Food and Drug Administration […]

Continued Clinical Success Reported with Unique Cutting-Edge Vessel Prep Device

First-of-its-kind metal-alloy scoring, cutting, and constraining structure (CS) device continues to elevate angioplasty treatment of chronic dialysis fistulas and grafts. PARK CITY, Utah, June 30, 2022 /PRNewswire/ — Transit Scientific shares successful outcomes on multiple fistula and graft cases using its XO Score Sheath Platform along with off-the-shelf percutaneous transluminal angioplasty (PTA) balloons. […]

Cytokinetics Announces Proposed Convertible Senior Notes Offering

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to […]

BioSig Announces Closing of Public Offering of Common Stock

Westport, CT, June 29, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced the closing and funding of its previously announced best efforts underwritten public […]

HeartBeam Expands Patient Population for Emergency Department Software Technology Solution

Expanded Scope of Clinical Validation Study Will Provide Access to a Broader Patient Population Company Expects to File 510K No Later Than August 15, 2022 SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, announced today […]

Hyperfine Names Scott Huennekens as Interim CEO

GUILFORD, Conn., June 29, 2022 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™, today announced that Dave Scott will step down from his role as President, Chief Executive Officer (CEO), and Board Member for personal reasons, effective July 29, 2022. Scott Huennekens, […]

Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent […]

Clarius Introduces Partnership with ImaCor That Powers New FDA Cleared Handheld Hemodynamic Ultrasound

Now made ultra-portable with Clarius, ImaCor’s Zura Handheld Hemodynamic Ultrasound™ has received FDA clearance as the world’s first handheld transesophageal echocardiography (TEE) system, enabling more clinicians to accurately determine appropriate interventions in real-time. VANCOUVER, BC and JERICHO, N.Y., June 29, 2022 /PRNewswire/ — Clarius Mobile Health, a leading provider of high-definition wireless ultrasound systems, and ImaCor Inc, […]

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

— HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma – — Immediately-available HAV, if approved, would represent significant and innovative advancements for vascular repair and replacement conduits– DURHAM, N.C., June 29, […]

Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study. REVERSE-HF will evaluate […]